UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Telogen effluvium

Author
Wilma Bergfeld, MD
Section Editor
Maria Hordinsky, MD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Telogen effluvium is a form of diffuse, nonscarring hair loss that presents as a transient or chronic loss of hair. Hair loss in telogen effluvium occurs as a result of an abnormal shift in follicular cycling that leads to the premature shedding of hair.

A wide variety of endogenous and exogenous factors have been linked to the induction of telogen effluvium. Examples include major surgery, serious illness, childbirth, protein or caloric malnutrition, drugs, and severe emotional distress. In some cases, the inciting cause is unclear.

The clinical features, diagnosis, and management of telogen effluvium will be reviewed here. An overview of the evaluation of patients with scalp hair loss is provided separately. (See "Evaluation and diagnosis of hair loss".)

EPIDEMIOLOGY

Data on the epidemiology of telogen effluvium are limited. The disorder is one of the most common forms of nonscarring hair loss for which patients present for clinical evaluation [1]. Telogen effluvium does not appear to have a predilection for particular racial or ethnic groups.

Most experts divide telogen effluvium into acute and chronic variants. Acute telogen effluvium may occur at any age, including infants and children [2,3]. For unclear reasons, women are more likely to present for evaluation of acute telogen effluvium than men [4]. Chronic telogen effluvium is much less common than the acute variant, and is most frequently diagnosed in women between the ages of 30 and 60 years [5,6]. Chronic telogen effluvium can further be subdivided into chronic and chronic-repetitive clinical presentations. (See 'Clinical features' below.)

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Jun 22 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg 2006; 25:51.
  2. Atton AV, Tunnessen WW Jr. Alopecia in children: the most common causes. Pediatr Rev 1990; 12:25.
  3. Nnoruka EN, Obiagboso I, Maduechesi C. Hair loss in children in South-East Nigeria: common and uncommon cases. Int J Dermatol 2007; 46 Suppl 1:18.
  4. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002; 27:389.
  5. Trüeb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges 2010; 8:284.
  6. Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996; 35:899.
  7. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol 1993; 129:356.
  8. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.
  9. Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.
  10. Bergfeld WF. Telogen Effluvium. In: Hair and Scalp Diseases: Medical, Surgical and Cosmetic treatments, McMichael A, Hordinsky M (Eds), Informa Health Care, 2008. p.119.
  11. Gizlenti S, Ekmekci TR. The changes in the hair cycle during gestation and the post-partum period. J Eur Acad Dermatol Venereol 2014; 28:878.
  12. Gilmore S, Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Australas J Dermatol 2010; 51:163.
  13. Cassano N, Amerio P, D'Ovidio R, Vena GA. Hair disorders associated with autoimmune connective tissue diseases. G Ital Dermatol Venereol 2014; 149:555.
  14. Perez-Mora N, Goren A, Velasco C, Bermudez F. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. Dermatol Ther 2014; 27:159.
  15. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54:824.
  16. Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010; 63:991.
  17. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003; 121:985.
  18. Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002; 147:982.
  19. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002; 27:396.
  20. Bregy A, Trueb RM. No association between serum ferritin levels >10 microg/l and hair loss activity in women. Dermatology 2008; 217:1.
  21. Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol 2013; 26:101.
  22. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320:1088.
  23. Bergfeld WF, Mulinari-Brenner F. Shedding: how to manage a common cause of hair loss. Cleve Clin J Med 2001; 68:256.
  24. Weedon D. Diseases of cutaneous appendages. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, Edinburgh 2010. p.397.
  25. Jordaan HF, Louw M. The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Am J Dermatopathol 1995; 17:158.
  26. Hillmann K, Blume-Peytavi U. Diagnosis of hair disorders. Semin Cutan Med Surg 2009; 28:33.
  27. Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012; 67:1040.
  28. Mayser P, Stapelkamp H, Krämer HJ, et al. Pityrialactone- a new fluorochrome from the tryptophan metabolism of Malassezia furfur. Antonie Van Leeuwenhoek 2003; 84:185.
  29. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol 2004; 123:455.
  30. Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66:e97.
  31. Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6:S1.
  32. Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol 2003; 139:1221.
  33. Tosti A, Piraccini BM, Sisti A, Duque-Estrada B. Hair loss in women. Minerva Ginecol 2009; 61:445.
  34. Sinclair R. Chronic telogen effluvium: a study of 5 patients over 7 years. J Am Acad Dermatol 2005; 52:12.